Thiazolidinediones

PreclinicalSmall molecule

Sanofi

Thiazolidinediones is one of 85 small molecule programs targeting Acute Pancreatitis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Acute PancreatitisActive, not recruiting

Pancreatic CancerActive, not recruiting

Heart FailureActive, not recruiting

Acute PancreatitisPreclinical

Active, not recruiting

Pancreatic CancerPreclinical

Active, not recruiting

Heart FailurePreclinical

Active, not recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Medrol

Pfizer

Preclinical

1 2

Byetta

AstraZeneca

Preclinical

1 3

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 4

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

Active Comparator

Moderna

Preclinical

1 8

Sulfonylureas

Eli Lilly

Preclinical

1 9

HS-20093

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Preclinical

1 10

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Type 2 Diabetes2 trials

Efficacy in Controlling Glycaemia With Victoza® (Liraglutide) as add-on to Metformin vs. OADs as add-on to Metformin After up to 104 Weeks of Treatment in Subjects With Type 2 Diabetes

Completed· Novo Nordisk logo

Novo Nordisk·Phase 4·NCT02730377·1,991 enrolled

Real-World Evaluation of Omarigliptin for Type 2 Diabetes Meliitus in Bangladesh

Not yet recruiting·—·Phase 4·NCT06449235·938 enrolled

Type 2 Diabetes Mellitus2 trials

A Study to Evaluate the Effectiveness and Safety Initiation and Titration of Insulin Glargine (U300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus (T2DM) Controlled on Oral Antidiabetic Drug Treatment in Turkey

Completed· Sanofi logo

Sanofi·Phase 4·NCT02954692·112 enrolled

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Completed· Johnson & Johnson logo

Johnson & Johnson··NCT03492580·714,582 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Thiazolidinediones. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Thiazolidinediones compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Thiazolidinediones. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: Sanofi

Thiazolidinediones

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Type 2 Diabetes2 trials

Type 2 Diabetes Mellitus2 trials

Heart Failure1 trial

Acute Pancreatitis1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News